| UK Earnings, Trading Statements Calendar | |
| Thursday, January 14 | |
| Tesco | Trading Statement |
| Burberry Group | Trading Statement |
| Associated British Foods | Trading Statement |
| Home Retail Group | Trading Statement |
| ASOS | Trading Statement |
| SuperGroup | Trading Statement |
| JD Sports Fashion | Trading Statement |
| Hilton Food Group | Trading Statement |
| Booker Group | Trading Statement |
| Mothercare | Trading Statement |
| Restaurant Group | Trading Statement |
| Moss Bros Group | Trading Statement |
| Ashmore Group | Trading Statement |
| Jupiter Fund Management | Trading Statement |
| Arbuthnot Banking Group | Trading Statement |
| Secure Trust Bank | Trading Statement |
| Lavendon Group | Trading Statement |
| McColl's Retail Group | Trading Statement |
| Braemar Shipping Services | Trading Statement |
| SIG | Trading Statement |
| William Hill | Trading Statement |
| Friday, January 15 | |
| Bonmarche | Trading Statement |
| Experian | Trading Statement |
| Bovis Homes Group | Trading Statement |
| NCC Group | Half Year Results |
| Monday, January 18 | |
| Rio Tinto | Q4 Operations Review (at 0830 AEDT) |
| Ibstock | Trading Statement |
| Tuesday, January 19 | |
| Unilever | Full Year Results |
| IG Group | Half Year Results |
| Mysale Group | Trading Statement |
| Revolution Bars Group | Trading Statement |
| Cairn Energy | Pre-close Update |
| Clinigen Group | Half Year Results |
| Evraz | Full Year Production Results |
| Wednesday, January 20 | |
| MoneySupermarket.com | Trading Statement |
| BHP Billiton (at 0830 AEST) | December Quarter Operational Review |
| Fresnillo | Q4 Production Results |
| Hochschild Mining | Q4 Production Results |
| Pets At Home | Trading Statement |
| JD Wetherspoon | Trading Statement |
| WH Smith | Christmas Trading Statement |
| BG Group | Operational & Trading update |
| Diploma | Trading Statement |
| Redx Pharma | Full Year Results |
| Copyright 2016 Alliance News Limited. All Rights Reserved. | |
10 Mar 2022 20:31
IN BRIEF: Redx Pharma notes encouraging safety data for RXC007
(Alliance News) Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Says phase 1 data presented at Virtual Interstitial Lung Disease Drug Development summit shows novel anti-fibrotic drug candidate, RXC007, possesses excellent safety and pharmacokinetic profile in both the single and multiple dose phase. No adverse events were observed following single doses of 2-70 milligrams, dosed once or twice in a day and no serious adverse events were observed in the multiple dose phase, dosed at 50mg twice daily for 14 days, with only transient, reversible mild adverse events observed, it says.
Read more